{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-080509","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2025-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.474091+00:00","generated_at":"2026-05-17T10:02:11.798729+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Incannex reports positive Phase 2 results for PSX-001 in Generalized Anxiety Disorder","bullets":["Psi-GAD (PSX-001) achieved a 12.8-point HAM-A reduction vs. 3.6 for placebo (p<0.0001) over 11 weeks.","44.1% of patients had clinical response (≥50% HAM-A reduction) and 27% achieved full remission (HAM-A ≤7).","GAD-7 scores fell 7.4 points, SDS improved 6.0 points, PHQ-9 dropped 3.9 points, all statistically significant.","No serious adverse events reported; only one subject withdrew from the 73-participant trial.","Incannex plans a multi-jurisdiction Phase 2 trial and is exploring strategic partnerships for PSX-001."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-080509","json":"https://secwatch.observer/filing/0001213900-25-080509.json","markdown":"https://secwatch.observer/filing/0001213900-25-080509.md","text":"https://secwatch.observer/filing/0001213900-25-080509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025080509/0001213900-25-080509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025080509/ea0254452-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T10:02:11.798729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}